{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:46:48Z","timestamp":1792039608381,"version":"4.4.0"},"reference-count":30,"publisher":"American Association for Cancer Research (AACR)","issue":"19","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>PAX5 is a member of the PAX family of developmental transcription factors with an important role in B-cell development. Its expression in normal adult tissue is limited to the hemopoietic system, but it is aberrantly expressed in a number of solid cancers and leukemias where it functions as an oncogene. We therefore hypothesized that anti-PAX5 immune responses could be used to target a number of malignancies without significant toxicity. We screened PAX5 peptides for the ability to bind HLA-A2 and identified a novel sequence, TLPGYPPHV (referred to as TLP). CTL lines against TLP were generated from peripheral blood of five normal HLA-A2\u2013positive blood donors and showed specific HLA-A2\u2013restricted killing against PAX5-expressing target cells. We generated high-avidity CTL clones from these lines capable of killing cells pulsed with &amp;lt;1 nmol\/L of TLP and killing a range of PAX5-expressing malignant cell lines. I.v. injection of an anti-PAX5 CTL clone into immunodeficient mice bearing s.c. human tumors resulted in specific growth inhibition of PAX5-expressing tumors. This knowledge can be used for the therapeutic generation of CTL lines or the cloning of high-avidity T-cell receptor genes for use in adoptive immunotherapy. [Cancer Res 2008;68(19):8058\u201365]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-0153","type":"journal-article","created":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:53:23Z","timestamp":1222822403000},"page":"8058-8065","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Development of Cellular Immune Responses against PAX5, a Novel Target for Cancer Immunotherapy"],"prefix":"10.1158","volume":"68","author":[{"given":"Mengyong","family":"Yan","sequence":"first","affiliation":[{"name":"1Units of Molecular Haematology and Cancer Biology, Institute of Child Health;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourredine","family":"Himoudi","sequence":"additional","affiliation":[{"name":"1Units of Molecular Haematology and Cancer Biology, Institute of Child Health;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Pule","sequence":"additional","affiliation":[{"name":"2Department of Haematology, University College London;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Sebire","sequence":"additional","affiliation":[{"name":"3Department of Histopathology, Great Ormond Street Hospital for Children, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Poon","sequence":"additional","affiliation":[{"name":"1Units of Molecular Haematology and Cancer Biology, Institute of Child Health;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Blair","sequence":"additional","affiliation":[{"name":"4Bristol Institute for Transfusion Sciences, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Williams","sequence":"additional","affiliation":[{"name":"1Units of Molecular Haematology and Cancer Biology, Institute of Child Health;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Anderson","sequence":"additional","affiliation":[{"name":"1Units of Molecular Haematology and Cancer Biology, Institute of Child Health;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,9,30]]},"reference":[{"key":"2022061700262926200_B1","doi-asserted-by":"crossref","unstructured":"Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer\u20082003; 3: 666\u201375.","DOI":"10.1038\/nrc1167"},{"key":"2022061700262926200_B2","doi-asserted-by":"crossref","unstructured":"Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol\u20082005; 23: 2346\u201357.","DOI":"10.1200\/JCO.2005.00.240"},{"key":"2022061700262926200_B3","doi-asserted-by":"crossref","unstructured":"Correale P, Walmsley K, Nieroda C, et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst\u20081997; 89: 293\u2013300.","DOI":"10.1093\/jnci\/89.4.293"},{"key":"2022061700262926200_B4","doi-asserted-by":"crossref","unstructured":"Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood\u20082000; 95: 2198\u2013203.","DOI":"10.1182\/blood.V95.7.2198.007k38_2198_2203"},{"key":"2022061700262926200_B5","doi-asserted-by":"crossref","unstructured":"Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med\u20082003; 198: 569\u201380.","DOI":"10.1084\/jem.20030590"},{"key":"2022061700262926200_B6","doi-asserted-by":"crossref","unstructured":"Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med\u20082003; 9: 279\u201386.","DOI":"10.1038\/nm827"},{"key":"2022061700262926200_B7","doi-asserted-by":"crossref","unstructured":"Himoudi N, Nabarro S, Yan M, et al. Development of anti-PAX3 immune responses; a target for cancer immunotherapy. Cancer Immunol Immunother\u20082007; 56: 1381\u201395.","DOI":"10.1007\/s00262-007-0294-3"},{"key":"2022061700262926200_B8","doi-asserted-by":"crossref","unstructured":"Busslinger M. Transcriptional control of early B cell development. Annu Rev Immunol\u20082004; 22: 55\u201379.","DOI":"10.1146\/annurev.immunol.22.012703.104807"},{"key":"2022061700262926200_B9","doi-asserted-by":"crossref","unstructured":"Urbanek P, Wang ZQ, Fetka I, Wagner EF, Busslinger M. Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5\/BSAP. Cell\u20081994; 79: 901\u201312.","DOI":"10.1016\/0092-8674(94)90079-5"},{"key":"2022061700262926200_B10","doi-asserted-by":"crossref","unstructured":"Nutt SL, Thevenin C, Busslinger M. Essential functions of Pax-5 (BSAP) in pro-B cell development. Immunobiology\u20081997; 198: 227\u201335.","DOI":"10.1016\/S0171-2985(97)80043-5"},{"key":"2022061700262926200_B11","doi-asserted-by":"crossref","unstructured":"Nutt SL, Heavey B, Rolink AG, Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature\u20081999; 401: 556\u201362.","DOI":"10.1038\/44076"},{"key":"2022061700262926200_B12","doi-asserted-by":"crossref","unstructured":"Torlakovic E, Slipicevic A, Robinson C, et al. Pax-5 expression in nonhematopoietic tissues. Am J Clin Pathol\u20082006; 126: 798\u2013804.","DOI":"10.1309\/XEC7JMW9YRM74RN0"},{"key":"2022061700262926200_B13","doi-asserted-by":"crossref","unstructured":"Tiacci E, Pileri S, Orleth A, et al. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. Cancer Res\u20082004; 64: 7399\u2013404.","DOI":"10.1158\/0008-5472.CAN-04-1865"},{"key":"2022061700262926200_B14","doi-asserted-by":"crossref","unstructured":"Lin P, Mahdavy M, Zhan F, et al. Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Mod Pathol\u20082004; 17: 1217\u201322.","DOI":"10.1038\/modpathol.3800169"},{"key":"2022061700262926200_B15","doi-asserted-by":"crossref","unstructured":"Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol\u20082007; 8: 463\u201370.","DOI":"10.1038\/ni1454"},{"key":"2022061700262926200_B16","doi-asserted-by":"crossref","unstructured":"Norhany S, Kouzu Y, Uzawa K, et al. Overexpression of PAX5 in oral carcinogenesis. Oncol Rep\u20082006; 16: 1003\u20138.","DOI":"10.3892\/or.16.5.1003"},{"key":"2022061700262926200_B17","doi-asserted-by":"crossref","unstructured":"Babjuk M, Soukup V, Mares J, et al. Association of PAX5 expression with clinical outcome in patients with TaT1 transitional cell carcinoma of the bladder. Urology\u20082006; 67: 756\u201361.","DOI":"10.1016\/j.urology.2005.10.053"},{"key":"2022061700262926200_B18","doi-asserted-by":"crossref","unstructured":"Baumann Kubetzko FB, Di Paolo C, Maag C, et al. The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. Carcinogenesis\u20082004; 25: 1839\u201346.","DOI":"10.1093\/carcin\/bgh190"},{"key":"2022061700262926200_B19","doi-asserted-by":"crossref","unstructured":"Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature\u20082007; 446: 758\u201364.","DOI":"10.1038\/nature05690"},{"key":"2022061700262926200_B20","doi-asserted-by":"crossref","unstructured":"Souabni A, Jochum W, Busslinger M. Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus. Blood\u20082007; 109: 281\u20139.","DOI":"10.1182\/blood-2006-03-009670"},{"key":"2022061700262926200_B21","doi-asserted-by":"crossref","unstructured":"Busslinger M, Klix N, Pfeffer P, Graninger PG, Kozmik Z. Deregulation of PAX-5 by translocation of the Emu enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma. Proc Natl Acad Sci U S A\u20081996; 93: 6129\u201334.","DOI":"10.1073\/pnas.93.12.6129"},{"key":"2022061700262926200_B22","doi-asserted-by":"crossref","unstructured":"Iida S, Rao PH, Ueda R, Chaganti RS, Dalla-Favera R. Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32). Leuk Lymphoma\u20081999; 34: 25\u201333.","DOI":"10.3109\/10428199909083377"},{"key":"2022061700262926200_B23","doi-asserted-by":"crossref","unstructured":"Morrison AM, Jager U, Chott A, et al. Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma. Blood\u20081998; 92: 3865\u201378.","DOI":"10.1182\/blood.V92.10.3865.422k01_3865_3878"},{"key":"2022061700262926200_B24","doi-asserted-by":"crossref","unstructured":"Park D, Jia H, Rajakumar V, Chamberlin HM. Pax2\/5\/8 proteins promote cell survival in C. elegans. Development\u20082006; 133: 4193\u2013202.","DOI":"10.1242\/dev.02614"},{"key":"2022061700262926200_B25","doi-asserted-by":"crossref","unstructured":"Robichaud GA, Nardini M, Laflamme M, Cuperlovic-Culf M, Ouellette RJ. Human Pax-5 C-terminal isoforms possess distinct transactivation properties and are differentially modulated in normal and malignant B cells. J Biol Chem\u20082004; 279: 49956\u201363.","DOI":"10.1074\/jbc.M407171200"},{"key":"2022061700262926200_B26","doi-asserted-by":"crossref","unstructured":"Kozbor D, Roder JC. Requirements for the establishment of high-titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique. J Immunol\u20081981; 127: 1275\u201380.","DOI":"10.4049\/jimmunol.127.4.1275"},{"key":"2022061700262926200_B27","doi-asserted-by":"crossref","unstructured":"Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest\u20081997; 100: 2757\u201365.","DOI":"10.1172\/JCI119822"},{"key":"2022061700262926200_B28","doi-asserted-by":"crossref","unstructured":"Nabarro S, Himoudi N, Papanastasiou A, et al. Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein. J Exp Med\u20082005; 202: 1399\u2013410.","DOI":"10.1084\/jem.20050730"},{"key":"2022061700262926200_B29","doi-asserted-by":"crossref","unstructured":"Cox CV, Evely RS, Oakhill A, et al. Characterization of acute lymphoblastic leukemia progenitor cells. Blood\u20082004; 104: 2919\u201325.","DOI":"10.1182\/blood-2004-03-0901"},{"key":"2022061700262926200_B30","doi-asserted-by":"crossref","unstructured":"Fuxa M, Busslinger M. Reporter gene insertions reveal a strictly B lymphoid-specific expression pattern of Pax5 in support of its B cell identity function. J Immunol\u20082007; 178: 8222\u20138.","DOI":"10.4049\/jimmunol.178.5.3031"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/19\/8058\/2596548\/8058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/19\/8058\/2596548\/8058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T01:52:19Z","timestamp":1684547539000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/19\/8058\/541288\/Development-of-Cellular-Immune-Responses-against"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,30]]},"references-count":30,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2008,9,30]]},"published-print":{"date-parts":[[2008,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-0153","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22373567","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373573.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373567.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373570","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373570.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373564.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373573","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22373564","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6497135.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6497135","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,30]]}}}